Research
Energy balance
At week 72, mean absolute T2D predicted risk score reductions were significantly greater in tirzepatide groups (5 mg, 12.4%; 10 mg, 14.4%; 15 mg, 14.7%) versus placebo (0.7%).
The specific dose of tirzepatide can be tailored to achieve greater reductions in diabetes risk.
StrongSupportsmedium confidence
At week 72, mean absolute T2D predicted risk score reductions were significantly greater in tirzepatide groups (5 mg, 12.4%; 10 mg, 14.4%; 15 mg, 14.7%) versus placebo (0.7%).
Why this rating
The study is a post hoc analysis of a randomized controlled trial.
Source
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the <scp>SURMOUNT</scp> ‐1 trial
Emily R. Hankosky et al. · Diabetes Obesity and Metabolism · 2023
otherCited 42×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →